Neisseria Gonorrhoeae Infections - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 70 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Neisseria Gonorrhoeae Infections - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Neisseria Gonorrhoeae Infections - Pipeline Review, H1 2015', provides an overview of the Neisseria Gonorrhoeae Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Neisseria Gonorrhoeae Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neisseria Gonorrhoeae Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Neisseria Gonorrhoeae Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Neisseria Gonorrhoeae Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Neisseria Gonorrhoeae Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Neisseria Gonorrhoeae Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Neisseria Gonorrhoeae Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Neisseria Gonorrhoeae Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Neisseria Gonorrhoeae Infections Overview 7
Therapeutics Development 8
Pipeline Products for Neisseria Gonorrhoeae Infections - Overview 8
Pipeline Products for Neisseria Gonorrhoeae Infections - Comparative Analysis 9
Neisseria Gonorrhoeae Infections - Therapeutics under Development by Companies 10
Neisseria Gonorrhoeae Infections - Therapeutics under Investigation by Universities/Institutes 12
Neisseria Gonorrhoeae Infections - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Neisseria Gonorrhoeae Infections - Products under Development by Companies 15
Neisseria Gonorrhoeae Infections - Products under Investigation by Universities/Institutes 16
Neisseria Gonorrhoeae Infections - Companies Involved in Therapeutics Development 17
Actavis plc 17
Adenium Biotech ApS 18
AstraZeneca PLC 19
BioDiem Ltd 20
Biolytics Pharma 21
Debiopharm International S.A. 22
GlaxoSmithKline plc 23
Sarepta Therapeutics, Inc. 24
Sumitomo Dainippon Pharma Co., Ltd. 25
Vertex Pharmaceuticals Incorporated 26
Neisseria Gonorrhoeae Infections - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 30
Assessment by Route of Administration 32
Assessment by Molecule Type 34
Drug Profiles 36
Antisense Oligonucleotide for Drug Resistant Neisseria Gonorrhoeae Infections - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Arenicin - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
AZD-0914 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
BDM-I - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Biologic for Neisseria Gonorrhoeae Infection - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Cribrostatin-6 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
dalbavancin - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Debio-1453 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
gonorrhoeae vaccine - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
GSK-2140944 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
SM-295291 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
SM-369926 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Small Molecule to Inhibit Tubulin for Neuroblastoma and Neisseria Gonorrhoeae Infections - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Small Molecules to Inhibit PBP2 for Neisseria Gonorrhoeae Infections - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Vaccine for Neisseria Gonorrhoeae Infection - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
VT-12008911 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Neisseria Gonorrhoeae Infections - Recent Pipeline Updates 54
Neisseria Gonorrhoeae Infections - Dormant Projects 64
Neisseria Gonorrhoeae Infections - Product Development Milestones 65
Featured News & Press Releases 65
Sep 09, 2014: Durata Therapeutics Presented Data at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 65
Jun 03, 2014: AstraZeneca's novel antibiotic candidate AZD0914 given Fast Track status by US FDA 67
Aug 08, 2012: BioDiem Receives European Patent For Antimicrobial Compound BDM-I 67
Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 69
Disclaimer 70

List of Tables
Number of Products under Development for Neisseria Gonorrhoeae Infections, H1 2015 8
Number of Products under Development for Neisseria Gonorrhoeae Infections - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 11
Number of Products under Investigation by Universities/Institutes, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Products under Investigation by Universities/Institutes, H1 2015 16
Neisseria Gonorrhoeae Infections - Pipeline by Actavis plc, H1 2015 17
Neisseria Gonorrhoeae Infections - Pipeline by Adenium Biotech ApS, H1 2015 18
Neisseria Gonorrhoeae Infections - Pipeline by AstraZeneca PLC, H1 2015 19
Neisseria Gonorrhoeae Infections - Pipeline by BioDiem Ltd, H1 2015 20
Neisseria Gonorrhoeae Infections - Pipeline by Biolytics Pharma, H1 2015 21
Neisseria Gonorrhoeae Infections - Pipeline by Debiopharm International S.A., H1 2015 22
Neisseria Gonorrhoeae Infections - Pipeline by GlaxoSmithKline plc, H1 2015 23
Neisseria Gonorrhoeae Infections - Pipeline by Sarepta Therapeutics, Inc., H1 2015 24
Neisseria Gonorrhoeae Infections - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 25
Neisseria Gonorrhoeae Infections - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2015 26
Assessment by Monotherapy Products, H1 2015 27
Number of Products by Stage and Target, H1 2015 29
Number of Products by Stage and Mechanism of Action, H1 2015 31
Number of Products by Stage and Route of Administration, H1 2015 33
Number of Products by Stage and Molecule Type, H1 2015 35
Neisseria Gonorrhoeae Infections Therapeutics - Recent Pipeline Updates, H1 2015 54
Neisseria Gonorrhoeae Infections - Dormant Projects, H1 2015 64